Hanmi Science, the holding company of Hanmi Group, posted an all-time high in sales last year on a consolidation basis.
Hanmi Science said on Feb. 5 that its preliminary results for last year were sales of 1.3568 trillion won, operating profit of 138.6 billion won, and net profit of 115.8 billion won. Each rose 5.7%, 40.2%, and 104.2% from a year earlier.
In the fourth quarter last year, sales were 343.9 billion won, operating profit was 37.6 billion won, and net profit was 31.1 billion won.
The company said growth in its own business institutional sector and improved performance at affiliates boosted profitability. It also cited an increase in equity-method gains from the expansion of high-margin businesses at affiliates and a decrease in one-off expenses as factors improving operating profit.
Healthcare business sales rose 19.6% year over year to 151.9 billion won. Onlinepharm, the pharmaceutical distribution institutional sector, posted sales of 1.1367 trillion won on the back of stronger sales of major over-the-counter (OTC) drugs.
JVM, a pharmaceutical automation systems company, saw its results improve thanks to higher overseas sales and expanded sales in the North American market of its vial automated dispensing solution "COUNTMATE."
In the medical device institutional sector, the adhesion barrier "Gadix" recorded annual sales of 23.1 billion won, and the hemostatic agent "Acticlot" posted sales of 8.1 billion won, up 77% from a year earlier due to the expansion of insurance codes.
The health and beauty (H&B) business also showed growth. Last year's sales of the cosmetics brand "PRO-CALM" were 12.1 billion won, up 75% from a year earlier. Major products in the cosmetics and food institutional sectors also saw increased sales.
Chief Executive Kim Jae-gyo said the company has "established itself as an operating holding company that generates results across diverse business areas."